glucovanillin: was extracted from green pods and simultaneously transformed to vanillin by a combination of enzyme activities involving cell wall degradation and glucovanillin hydrolysis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3648225 |
| CHEBI ID | 168797 |
| SCHEMBL ID | 1646304 |
| SCHEMBL ID | 20991565 |
| MeSH ID | M0410174 |
| Synonym |
|---|
| STK737742 |
| 4-formyl-2-methoxyphenyl hexopyranoside |
| CHEBI:168797 |
| 3-methoxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzaldehyde |
| vanilloside |
| glucovanillin |
| ZINC00104975 |
| AKOS001204135 |
| AKOS016295649 |
| 4-formyl-2-methoxyphenyl beta-d-galactopyranoside |
| BBL012293 |
| FT-0675779 |
| SCHEMBL1646304 |
| SCHEMBL20991565 |
| 4-formyl-2-methoxyphenyl beta-d-glucopyranoside |
| mfcd09025610 |
| 83662-01-5 |
| 1093407-53-4 |
| mfcd00210591 |
| SY113198 |
| Z57728541 |
| 3-methoxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzaldehyde |
| VS-03262 |
| glucovanillin - natural |
| vanillin 4-o-(c)micro-d-glucoside |
| BCP30057 |
| 3-methoxy-4-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)benzaldehyde |
| B1999-093052 |
| DTXSID40871695 |
| STARBLD0040985 |
| EN300-26583999 |
| Class | Description |
|---|---|
| glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.64) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||